Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results

A. M. van der Laan; A. Hirsch; R. Nijveldt; P. A. van der Vleuten; W. J. van der Giessen; P. A. Doevendans; J. Waltenberger; J. M. ten Berg; W. R. M. Aengevaeren; J. J. Zwaginga; B. J. Biemond; A. C. van Rossum; J. G. P. Tijssen; F. Zijlstra; J. J. Piek

Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results

A. M. van der Laan, A. Hirsch, R. Nijveldt, P. A. van der Vleuten, W. J. van der Giessen, P. A. Doevendans, J. Waltenberger, J. M. ten Berg, W. R. M. Aengevaeren, J. J. Zwaginga, B. J. Biemond, A. C. van Rossum, J. G. P. Tijssen, F. Zijlstra, J. J. Piek^*

^*Bijbehorende auteur voor dit werk

Onderzoeksoutput › Academic › peer review

39 Citaten (Scopus)

Samenvatting

During the last decennium, the role of bone marrow mononuclear cells (BMMC) has been underscored in the healing process after acute myocardial infarction (AMI). Although these cells improve left ventricular recovery after AMI in experimental studies, results from large-scale randomised trials investigating BMMC therapy in patients with AMI have shown contradictory results. To address this issue the HEBE Study was designed, a multicentre, randomised trial, evaluating the effects of intracoronary, infusion of BMMCs and the effects of intracoronary infusion of peripheral blood mononuclear cells after primary percutaneous coronary intervention. The primary endpoint of the HEBE trial is the change in regional myocardial function in dysfunctional segments at four months relative to baseline, based on segmental analysis as measured by magnetic resonance imaging. The results from the HEBE trial will provide detailed information about the effects of intracoronary, BMMC therapy on post-infact left ventricular. In addition, further analysis of the data and material obtained may provide important mechanistic insights into the contribution of BMMCs to natural recovery from AMI as well as the response to cell therapy. This may significantly contribute to the development of improved cell-based therapies, aiming at optimising post-infarct recovery and preventing heart failure. (Neth Hcart J 2008;16:436-9.)

Originele taal-2	English
Pagina's (van-tot)	436-439
Aantal pagina's	4
Tijdschrift	Netherlands Heart Journal
Volume	16
Nummer van het tijdschrift	12
Status	Published - dec.-2008

Handle.net

Permanente koppeling

Citeer dit

van der Laan, A. M., Hirsch, A., Nijveldt, R., van der Vleuten, P. A., van der Giessen, W. J., Doevendans, P. A., Waltenberger, J., ten Berg, J. M., Aengevaeren, W. R. M., Zwaginga, J. J., Biemond, B. J., van Rossum, A. C., Tijssen, J. G. P., Zijlstra, F., & Piek, J. J. (2008). Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results. Netherlands Heart Journal, 16(12), 436-439.

@article{e8db027b8e0a4e8aada65fd872f71ee8,

title = "Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results",

abstract = "During the last decennium, the role of bone marrow mononuclear cells (BMMC) has been underscored in the healing process after acute myocardial infarction (AMI). Although these cells improve left ventricular recovery after AMI in experimental studies, results from large-scale randomised trials investigating BMMC therapy in patients with AMI have shown contradictory results. To address this issue the HEBE Study was designed, a multicentre, randomised trial, evaluating the effects of intracoronary, infusion of BMMCs and the effects of intracoronary infusion of peripheral blood mononuclear cells after primary percutaneous coronary intervention. The primary endpoint of the HEBE trial is the change in regional myocardial function in dysfunctional segments at four months relative to baseline, based on segmental analysis as measured by magnetic resonance imaging. The results from the HEBE trial will provide detailed information about the effects of intracoronary, BMMC therapy on post-infact left ventricular. In addition, further analysis of the data and material obtained may provide important mechanistic insights into the contribution of BMMCs to natural recovery from AMI as well as the response to cell therapy. This may significantly contribute to the development of improved cell-based therapies, aiming at optimising post-infarct recovery and preventing heart failure. (Neth Hcart J 2008;16:436-9.)",

keywords = "PROGENITOR CELLS, INTRACORONARY INFUSION, MONONUCLEAR-CELLS, PERIPHERAL-BLOOD, TRANSPLANTATION, REGENERATION, MULTICENTER, DESIGN, AMI",

author = "{van der Laan}, {A. M.} and A. Hirsch and R. Nijveldt and {van der Vleuten}, {P. A.} and {van der Giessen}, {W. J.} and Doevendans, {P. A.} and J. Waltenberger and {ten Berg}, {J. M.} and Aengevaeren, {W. R. M.} and Zwaginga, {J. J.} and Biemond, {B. J.} and {van Rossum}, {A. C.} and Tijssen, {J. G. P.} and F. Zijlstra and Piek, {J. J.}",

year = "2008",

month = dec,

language = "English",

volume = "16",

pages = "436--439",

journal = "Netherlands Heart Journal",

issn = "0929-7456",

publisher = "Bohn, Stafleu, Van Loghum",

number = "12",

}

van der Laan, AM, Hirsch, A, Nijveldt, R, van der Vleuten, PA, van der Giessen, WJ, Doevendans, PA, Waltenberger, J, ten Berg, JM, Aengevaeren, WRM, Zwaginga, JJ, Biemond, BJ, van Rossum, AC, Tijssen, JGP, Zijlstra, F & Piek, JJ 2008, 'Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results', Netherlands Heart Journal, vol. 16, nr. 12, blz. 436-439.

TY - JOUR

T1 - Bone marrow cell therapy after acute myocardial infarction

T2 - the HEBE trial in perspective, first results

AU - van der Laan, A. M.

AU - Hirsch, A.

AU - Nijveldt, R.

AU - van der Vleuten, P. A.

AU - van der Giessen, W. J.

AU - Doevendans, P. A.

AU - Waltenberger, J.

AU - ten Berg, J. M.

AU - Aengevaeren, W. R. M.

AU - Zwaginga, J. J.

AU - Biemond, B. J.

AU - van Rossum, A. C.

AU - Tijssen, J. G. P.

AU - Zijlstra, F.

AU - Piek, J. J.

PY - 2008/12

Y1 - 2008/12

N2 - During the last decennium, the role of bone marrow mononuclear cells (BMMC) has been underscored in the healing process after acute myocardial infarction (AMI). Although these cells improve left ventricular recovery after AMI in experimental studies, results from large-scale randomised trials investigating BMMC therapy in patients with AMI have shown contradictory results. To address this issue the HEBE Study was designed, a multicentre, randomised trial, evaluating the effects of intracoronary, infusion of BMMCs and the effects of intracoronary infusion of peripheral blood mononuclear cells after primary percutaneous coronary intervention. The primary endpoint of the HEBE trial is the change in regional myocardial function in dysfunctional segments at four months relative to baseline, based on segmental analysis as measured by magnetic resonance imaging. The results from the HEBE trial will provide detailed information about the effects of intracoronary, BMMC therapy on post-infact left ventricular. In addition, further analysis of the data and material obtained may provide important mechanistic insights into the contribution of BMMCs to natural recovery from AMI as well as the response to cell therapy. This may significantly contribute to the development of improved cell-based therapies, aiming at optimising post-infarct recovery and preventing heart failure. (Neth Hcart J 2008;16:436-9.)

AB - During the last decennium, the role of bone marrow mononuclear cells (BMMC) has been underscored in the healing process after acute myocardial infarction (AMI). Although these cells improve left ventricular recovery after AMI in experimental studies, results from large-scale randomised trials investigating BMMC therapy in patients with AMI have shown contradictory results. To address this issue the HEBE Study was designed, a multicentre, randomised trial, evaluating the effects of intracoronary, infusion of BMMCs and the effects of intracoronary infusion of peripheral blood mononuclear cells after primary percutaneous coronary intervention. The primary endpoint of the HEBE trial is the change in regional myocardial function in dysfunctional segments at four months relative to baseline, based on segmental analysis as measured by magnetic resonance imaging. The results from the HEBE trial will provide detailed information about the effects of intracoronary, BMMC therapy on post-infact left ventricular. In addition, further analysis of the data and material obtained may provide important mechanistic insights into the contribution of BMMCs to natural recovery from AMI as well as the response to cell therapy. This may significantly contribute to the development of improved cell-based therapies, aiming at optimising post-infarct recovery and preventing heart failure. (Neth Hcart J 2008;16:436-9.)

KW - PROGENITOR CELLS

KW - INTRACORONARY INFUSION

KW - MONONUCLEAR-CELLS

KW - PERIPHERAL-BLOOD

KW - TRANSPLANTATION

KW - REGENERATION

KW - MULTICENTER

KW - DESIGN

KW - AMI

M3 - Article

SN - 0929-7456

VL - 16

SP - 436

EP - 439

JO - Netherlands Heart Journal

JF - Netherlands Heart Journal

IS - 12

ER -